Genomics research and diagnostics company MedGenome said today that it closed a $30 million Series C round led by Sequoia India and Sofina. Zodius Capital, the co-founder & former CEO of Infosys, Kris Gopalakrishnan, and former Cognizant CEO Lakshmi Narayanan also participated in the round. The Foster City, Calif.-based company said it plans to use […]
Genomics/Molecular Diagnostics
Philips, Illumina to launch precision medicine cancer program with Navican
Royal Philips (NYSE:PHG) and Intermountain Healthcare company Navican inked an agreement today to launch a precision health informatics solution aimed at improving outcomes for late stage cancer patients. The program is slated to leverage Navican‘s TheraMap Precision Cancer Care services and Philips’ IntelliSpace Genomics platform, which uses Illumina‘s next-gen genomic sequencing technologies. At Utah-based Intermountain Healthcare’s […]
23andMe is back: FDA allows marketing of genetic health risk tests
FDA this month allowed genetic testing company 23andMe to market genetic health risk tests for 10 diseases and conditions including Parkinson’s disease and late-onset Alzheimer’s disease. The de novo premarket review authorization, announced April 6, also included celiac disease, which results in the inability to digest gluten; alpha-1 antitrypsin deficiency, which raises the risk of […]
Illumina, Novogene ink development deal for next-gen sequencing tech
Illumina (NSDQ:ILMN) and genomic service company Novogene said today they entered into an agreement to jointly develop advanced clinical applications for reproductive health and oncology based on next-generation sequencing technology. The collaboration will focus on providing advanced, integrated sequencing solutions to the clinical market, the company said. The 2 companies are slated to work together to create […]
Medtronic says a pair of studies show genetic link to sudden cardiac death
Medtronic (NYSE:MDT) today said 1st-of-a-kind results from a pair of independent clinical trials discovered a gene linked to abnormal heart rhythms that can lead to sudden cardiac death. Fridley, Minn.-based Medtronic said the studies, Discovery and Oregon SUDS, found a gene associated with SCD in patients with implantable cardioverter defibrillators. Results were presented over the weekend […]
PDI rejects Digirad buyout offer, buys RedPath instead
PDI has bought RedPath Integrated Pathology just days after rejecting a tentative buyout offer from Digirad Corp. (NSDQ:DRAD).
BD buys Irish next-gen sequencing startup GenCell Biosystems
Nanosphere might go up on the auction block
A year after closing on a $30 million offering, Nanosphere said yesterday that it’s hired an investment bank to examine the proverbial "strategic alternatives," including a possible sale of the molecular diagnostics technology business.
HealthQuest Capital raises $110M for healthcare investments
HealthQuest Capital is looking to make some moves healthcare with its newly raised $110 million fund, looking for unmet needs in medical devices, diagnostics and information technology.
Exact Sciences lands 1st joint approval through FDA-CMS parallel review
Wisconsin-based Exact Sciences (NSDQ:EXAS) won landmark approval for its Cologuard home colorectal cancer test, becoming the 1st company to successfully navigate a pilot program for parallel review by both FDA and Medicare regulators.
Press Release: FDA approves first non-invasive DNA screening test for colorectal cancer
The U.S. Food and Drug Administration today approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or precursors to cancer.